Homepage News News 13/11/2026 Development of Red Yeast Rice Fermented Using Monascus purpureus C5.17 for potential cholesterol-lowering applications (SHTP) – This study, conducted by researchers at the Biotechnology Center of Ho Chi Minh City, demonstrated the potential of the Vietnamese isolate Monascus purpureus C5.17 for producing red yeast rice enriched with valuable bioactive compounds. The resulting product exhibited lipid-modulating effects in a mouse model, including reductions in low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels, with a potential improvement in high-density lipoprotein cholesterol (HDL-C). Furthermore, citrinin was not detected in the product, highlighting its potential for the development of red yeast rice with improved mycotoxin safety. At the Biotechnology Center of Ho Chi Minh City, the research team isolated nine Monascus purpureus strains, performed multilocus sequence analysis (MLSA) using five genetic markers (ITS, LSU, benA, rpb2, and cmdA), and established a molecular and biochemical profile of strains capable of producing monacolin K with no detectable citrinin. Among these isolates, M. purpureus C5.17 demonstrated the potential to produce natural azaphilone pigments and a diverse array of secondary metabolites, including monacolin K, sterols, steroids, triterpenoids, and other potentially bioactive compounds. Figure 1. Monascus purpureus C5.17 was cultured on different media: PDA, MCM, MGA, SDAY, and PGA Red yeast rice (RYR) is a fermented rice product produced using fungi of the genus Monascus. It has a long history of use in traditional East Asian medicine and has been traditionally associated with cholesterol reduction, improved blood circulation, and lipid metabolism regulation. Figure 2. Red yeast rice produced by fermentation with Monascus purpureus C5.17 Monascus purpureus C5.17 demonstrated the ability to biosynthesize monacolin K, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in endogenous cholesterol biosynthesis, thereby potentially contributing to reductions in total cholesterol and low-density lipoprotein cholesterol (LDL-C). Furthermore, liquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis detected no citrinin in the C5.17-derived red yeast rice powder, highlighting the strain’s potential for developing monacolin K-enriched red yeast rice products with an improved mycotoxin safety profile. Figure 3. Analysis of Citrinin and Monacolin K in Red Yeast Rice Powder Furthermore, LC–QTOF–MS/MS profiling characterized the chemical composition of the red yeast rice product and revealed a diverse array of metabolites, including monacolin K, flavonoids, sterols, unsaturated fatty acids, and terpenoids, several of which have been associated with cardiovascular health and lipid metabolism. These findings highlight the potential of red yeast rice produced using Monascus purpureus C5.17 as a source of bioactive compounds. Pharmacological efficacy and safety in healthy ICR mice. Following 28 days of treatment at doses of 100, 250, and 500 mg/kg, red yeast rice did not induce abnormal elevations in blood glucose levels. The treatment was also associated with reduced serum triglyceride (TG) levels and increased high-density lipoprotein cholesterol (HDL-C). A renal safety assessment based on the blood urea nitrogen-to-creatinine ratio (urea/creatinine) yielded values ranging from 21:1 to 55:1, within the reported physiological reference interval of 9.4:1–147.5:1. Effects on lipid profiles in streptozotocin (STZ)-induced diabetic mice. After 28 days of treatment, red yeast rice administered at all three dose levels reduced total cholesterol (TC) and LDL-C compared with the untreated diabetic control group. LDL-C levels in the treated groups ranged from 41.79 to 50.26 mg/dL. HDL-C levels showed no statistically significant changes overall, although a value of 76.15 ± 11.17 mg/dL was recorded in the STZ-2 group. TG levels decreased in selected treatment groups, particularly at doses of 250 and 500 mg/kg, suggesting a potential lipid-modulating effect. The overall improvements in lipid parameters showed a trend comparable to those observed in the Diamicron-treated group. Notably, the survival rate was 100% across all red yeast rice-treated groups throughout the experimental period. Collectively, these preliminary findings indicate that red yeast rice produced using Monascus purpureus C5.17 may improve dyslipidemia in STZ-induced diabetic mice. Scientific Basis for Applied Research Research on Monascus purpureus C5.17 conducted at the Biotechnology Center of Ho Chi Minh City has yielded a red yeast rice material with promising lipid-modulating effects and no detectable citrinin under the analytical conditions employed. These findings provide a scientific basis for further developing functional foods and health supplements intended to support lipid management and cardiovascular health. Further investigations, including comprehensive safety assessments, efficacy validation, and clinical studies, are needed to establish its potential role in reducing atherosclerotic risk and promoting cardiovascular health in the general population./. Dao Nu Dieu Hong Biotechnology Center of Ho Chi Minh City. 653 view